Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 48

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Menichini, Paola, Monti, Paola, Speciale, Andrea, Cutrona, Giovanna, Matis, Serena, Fais, Franco, Taiana, Elisa, Neri, Antonino, Bomben, Riccardo, Gentile, Massimo, Gattei, Valter, Ferrarini, Manlio, Morabito, Fortunato, Fronza, Gilberto · 2021 · Cells

Abstract

Because of its role in the regulation of the cell cycle, DNA damage response, apoptosis, DNA repair, cell migration, autophagy, and cell metabolism, the TP53 tumor suppressor gene is a key player for cellular homeostasis. TP53 gene is mutated in more than 50% of human cancers, although its overall dysfunction may be even more frequent. TP53 mutations are detected in a lower percentage of hematological malignancies compared to solid tumors, but their frequency generally increases with disease progression, generating adverse effects such as resistance to chemotherapy. Due to the crucial role of P53 in therapy response, several molecules have been developed to re-establish the wild-type P53 function to mutant P53. PRIMA-1 and its methylated form PRIMA-1Met (also named APR246) are capable of restoring the wild-type conformation to mutant P53 and inducing apoptosis in cancer cells; however, they also possess mutant P53-independent properties. This review presents the activities of PRIMA-1 and PRIMA-1Met/APR246 and describes their potential use in hematological malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells10010098

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 79

  1. Haupt, 1997, Mdm2 promotes the rapid degradation of p53, Nature, 387, 296, 10.1038/387296a0 · DOI · Paper page
  2. Zhou, 2019, Mutant p53 in cancer therapy—the barrier or the path, J. Mol. Cell Biol., 11, 293, 10.1093/jmcb/mjy072 · DOI · Paper page
  3. Dittmer, 1993, Gain of function mutations in p53, Nat. Genet., 4, 42, 10.1038/ng0593-42 · DOI · Paper page
  4. Leroy, 2014, TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade, Hum. Mutat., 35, 672, 10.1002/humu.22552 · DOI · Paper page
  5. Dearth, 2007, Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers, Carcinogenesis, 28, 289, 10.1093/carcin/bgl132 · DOI · Paper page
  6. Zenz, 2008, Molecular diagnostics in chronic lymphocytic leukemia—Pathogenetic and clinical implications, Leuk. Lymphoma, 49, 864, 10.1080/10428190701882955 · DOI
  7. Zhao, 2010, Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA, Cell Cycle, 9, 1847, 10.4161/cc.9.9.11545 · DOI · Paper page
  8. Konopleva, 2020, MDM2 inhibition: An important step forward in cancer therapy, Leukemia, 34, 2858, 10.1038/s41375-020-0949-z · DOI · Paper page
  9. Schulz-Heddergott, R., and Moll, U. (2018). Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. Cancers, 10. · DOI
  10. Wang, 2011, Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP, J. Cell. Biochem., 112, 509, 10.1002/jcb.22941 · DOI
  11. Foggetti, 2017, Gambogic acid counteracts mutant p53 stability by inducing autophagy, Biochim. Biophys. Acta Mol. Cell Res., 1864, 382, 10.1016/j.bbamcr.2016.11.023 · DOI
  12. Foggetti, 2019, Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival, Biosci. Rep., 39, BSR20181345, 10.1042/BSR20181345 · DOI
  13. Vassilev, 2004, In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
  14. Selivanova, 2014, Wild type p53 reactivation: From lab bench to clinic, FEBS Lett., 588, 2628, 10.1016/j.febslet.2014.03.049 · DOI
  15. Trepel, 2010, Targeting the dynamic HSP90 complex in cancer, Nat. Rev. Cancer, 10, 537, 10.1038/nrc2887 · DOI · Paper page
  16. Li, 2011, Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells, Mol. Cancer Res., 9, 577, 10.1158/1541-7786.MCR-10-0534 · DOI · Paper page
  17. Alexandrova, 2017, Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: A new promise in cancer therapy, Cell Death Differ., 24, 3, 10.1038/cdd.2016.145 · DOI
  18. Cheung, 2009, The significance of TP53 in lymphoid malignancies: Mutation prevalence, regulation, prognostic impact and potential as a therapeutic target, Br. J. Haematol., 146, 257, 10.1111/j.1365-2141.2009.07739.x · DOI
  19. Gaidano, 1991, p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. USA, 88, 5413, 10.1073/pnas.88.12.5413 · DOI · Paper page
  20. Nahi, 2008, Mutated and non-mutated TP53 as targets in the treatment of leukaemia, Br. J. Haematol., 141, 445, 10.1111/j.1365-2141.2008.07046.x · DOI · Paper page
  21. Agirre, 2003, TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia, Mol. Carcinog., 38, 201, 10.1002/mc.10159 · DOI
  22. Chng, 2007, Clinical significance of TP53 mutation in myeloma, Leukemia, 21, 582, 10.1038/sj.leu.2404524 · DOI
  23. Chiorazzi, 2005, Chronic Lymphocytic Leukemia, N. Engl. J. Med., 352, 804, 10.1056/NEJMra041720 · DOI · Paper page
  24. Hallek, 2018, Chronic lymphocytic leukaemia, Lancet, 391, 1524, 10.1016/S0140-6736(18)30422-7 · DOI · Paper page
  25. Gentile, 2018, Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab, Leukemia, 32, 1869, 10.1038/s41375-018-0100-6 · doi:10.1038/s41375-018-0100-6
  26. Stilgenbauer, 2000, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, N. Engl. J. Med., 343, 1910, 10.1056/NEJM200012283432602 · DOI · Paper page
  27. Rossi, 2014, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, 123, 2139, 10.1182/blood-2013-11-539726 · DOI · Paper page
  28. Monti, 2020, Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?, Front. Oncol., 10, 593383, 10.3389/fonc.2020.593383 · DOI
  29. Buccheri, 2018, Prognostic and therapeutic stratification in CLL: Focus on 17p deletion and p53 mutation, Ann. Hematol., 97, 2269, 10.1007/s00277-018-3503-6 · DOI
  30. Rossi, 2009, The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness, Clin. Cancer Res., 15, 995, 10.1158/1078-0432.CCR-08-1630 · DOI · Paper page
  31. Zenz, 2010, TP53 mutation profile in chronic lymphocytic leukemia: Evidence for a disease specific profile from a comprehensive analysis of 268 mutations, Leukemia, 24, 2072, 10.1038/leu.2010.208 · DOI · Paper page
  32. Stilgenbauer, 2014, Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial, Blood, 123, 3247, 10.1182/blood-2014-01-546150 · DOI · Paper page
  33. Cymbalista, 2016, Genetic profiling of CLL: A ‘TP53 addict’ perspective, Cell Death Dis., 7, e2042, 10.1038/cddis.2015.415 · doi:10.1038/cddis.2015.415
  34. Malcikova, 2018, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, Leukemia, 32, 1070, 10.1038/s41375-017-0007-7 · DOI · Paper page
  35. Burger, 2015, Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, N. Engl. J. Med., 373, 2425, 10.1056/NEJMoa1509388 · DOI · Paper page
  36. Burger, 2020, Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study, Leukemia, 34, 787, 10.1038/s41375-019-0602-x · DOI · Paper page
  37. Shanafelt, 2019, Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia, N. Engl. J. Med., 381, 432, 10.1056/NEJMoa1817073 · DOI · Paper page
  38. Woyach, 2018, Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL, N. Engl. J. Med., 379, 2517, 10.1056/NEJMoa1812836 · DOI · Paper page
  39. Furman, 2014, Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, N. Engl. J. Med., 370, 997, 10.1056/NEJMoa1315226 · DOI · Paper page
  40. Sharman, 2019, Final Results of a Randomized, Phase III Study of Rituximab with or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia, J. Clin. Oncol., 37, 1391, 10.1200/JCO.18.01460 · DOI · Paper page
  41. Zhang, 2020, Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol., 21, 1188, 10.1016/S1470-2045(20)30443-5 · DOI · Paper page
  42. Morabito, 2020, TP53 dysfunction in chronic lymphocytic leukemia: Clinical relevance in the era of B-cell receptors and BCL-2 inhibitors, Expert Opin. Investig. Drugs, 29, 869, 10.1080/13543784.2020.1783239 · DOI
  43. Ahn, I.E., Tian, X., Ipe, D., Cheng, M., Albitar, M., Tsao, L.C., Zhang, L., Ma, W., Herman, S.E.M., and Gaglione, E.M. (2020). Prediction of Outcome in Patients with Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. J. Clin. Oncol. · DOI
  44. Monti, 2020, Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: Results of the O-CLL1 study in early stage patients, Sci. Rep., 10, 18427, 10.1038/s41598-020-75364-3 · doi:10.1038/s41598-020-75364-3
  45. Best, 2009, A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease, Leukemia, 23, 212, 10.1038/leu.2008.260 · doi:10.1038/leu.2008.260
  46. Bykov, 2002, Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: A statistical analysis of information in the National Cancer Institute database, Carcinogenesis, 23, 2011, 10.1093/carcin/23.12.2011 · DOI · Paper page
  47. Wang, 2007, PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax, Biochem. Biophys. Res. Commun., 352, 203, 10.1016/j.bbrc.2006.11.006 · DOI · Paper page
  48. Liang, 2009, PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein, Int. J. Oncol., 35, 1015
  49. Zandi, 2011, PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53, Clin. Cancer Res., 17, 2830, 10.1158/1078-0432.CCR-10-3168 · DOI · Paper page
  50. Messina, 2012, Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells, Int. J. Cancer, 130, 2259, 10.1002/ijc.26228 · DOI
  51. Farhadi, 2017, PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc. Anticancer, Drugs, 28, 51
  52. Lee, 2006, Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells, Biochem. Biophys. Res. Commun., 349, 1117, 10.1016/j.bbrc.2006.08.152 · DOI
  53. Chipuk, 2003, Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription, Cancer Cell, 4, 371, 10.1016/S1535-6108(03)00272-1 · DOI · Paper page
  54. Lambert, 2010, Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis, Oncogene, 29, 1329, 10.1038/onc.2009.425 · DOI
  55. Magrini, 2008, PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells, J. Cell. Biochem., 104, 2363, 10.1002/jcb.21794 · DOI
  56. Izetti, 2014, PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines, Investig. New Drugs, 32, 783, 10.1007/s10637-014-0090-9 · DOI
  57. Liu, 2015, APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoalima, Gut, 64, 1506, 10.1136/gutjnl-2015-309770 · DOI
  58. Deben, 2016, APR-246 (PRIMA-1 MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines, Cancer Lett., 375, 313, 10.1016/j.canlet.2016.03.017 · DOI
  59. Nahi, 2004, Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion, Br. J. Haematol., 127, 285, 10.1111/j.1365-2141.2004.05210.x · DOI · Paper page
  60. Donehower, 2019, Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas, Cell Rep., 28, 1370, 10.1016/j.celrep.2019.07.001 · DOI · Paper page
  61. Nahi, 2006, PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion, Br. J. Haematol., 132, 230, 10.1111/j.1365-2141.2005.05851.x · DOI
  62. Ali, 2011, APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells, Eur. J. Haematol., 86, 206, 10.1111/j.1600-0609.2010.01557.x · DOI · Paper page
  63. Wassman, 2013, Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53, Nat. Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
  64. Saha, 2013, PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa, Mol. Cancer Ther., 12, 2331, 10.1158/1535-7163.MCT-12-1166 · DOI · Paper page
  65. Bao, 2011, PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo, Cell Cycle Georget. Tex, 10, 301, 10.4161/cc.10.2.14538 · DOI
  66. Supiot, 2008, PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status, Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., 86, 407, 10.1016/j.radonc.2008.01.001 · DOI
  67. Shi, 2008, In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249, Carcinogenesis, 29, 1428, 10.1093/carcin/bgm266 · DOI
  68. Tessoulin, 2014, PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, 124, 1626, 10.1182/blood-2014-01-548800 · DOI · Paper page
  69. Grellety, T., Laroche-Clary, A., Chaire, V., Lagarde, P., Chibon, F., Neuville, A., and Italiano, A. (2015). PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer, 15. · DOI
  70. Teoh, 2016, PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation, Oncotarget, 7, 61806, 10.18632/oncotarget.11241 · DOI
  71. Ali, 2016, Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells, Br. J. Haematol., 174, 117, 10.1111/bjh.14036 · DOI · Paper page
  72. Lisek, 2018, Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells, Oncotarget, 9, 20508, 10.18632/oncotarget.24974 · DOI
  73. Saha, 2016, MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc, Oncotarget, 7, 7149, 10.18632/oncotarget.6880 · DOI
  74. Russo, 2013, PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53, Biochim. Biophys. Acta, 1833, 1904, 10.1016/j.bbamcr.2013.03.020 · DOI
  75. Russo, 2010, PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells, Biochem. Biophys. Res. Commun., 402, 345, 10.1016/j.bbrc.2010.10.031 · DOI
  76. Jaskova, 2020, PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells, Leuk. Res., 89, 106288, 10.1016/j.leukres.2019.106288 · DOI
  77. Sallman, 2020, To target the untargetable: Elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia, Haematologica, 105, 1470, 10.3324/haematol.2020.249060 · DOI · Paper page
  78. Jain, 2019, Ibrutinib and Venetoclax for First-Line Treatment of CLL, N. Engl. J. Med., 380, 2095, 10.1056/NEJMoa1900574 · DOI · Paper page
  79. Rozovski, 2016, Metabolism pathways in chronic lymphocytic leukemia, Leuk. Lymphoma, 57, 758, 10.3109/10428194.2015.1106533 · DOI

Cited by

See all 48

Metadata

Authors
Menichini, P., Monti, P., Speciale, A., Cutrona, G., Matis, S., Fais, F., Taiana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., Ferrarini, M., Morabito, F., & Fronza, G.
Venue
Cells
Publisher
MDPI AG
Published
2021-01-07
Volume
10
Issue
1
Pages
98
ISSN
2073-4409
Cited by
48
References
17
Language
en
Funders
  • Associazione Italiana per la Ricerca sul Cancro (Grant 5 x mille n.9980, n.14326, n.15426, and n. 5506)
  • AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 (n.16695)
  • Italian Ministry of Health 5x1000 (Funds 2013, 2014, 2015, 2016)
  • Italian Ministry of Health Current Reserach (funds 2016)
  • Italian Ministry of Health Alleanza contro il Cancro (ACC) (Hematology network)
  • Compagnia S. Paolo Turin, Italy (project 2017.0526)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? https://app.cochat.ai/papers/10.3390/cells10010098
The paper
Menichini, P., Monti, P., Speciale, A., Cutrona, G., Matis, S., Fais, F., Taiana, E., Neri, A., Bomben, R., Gentile, M., Gattei, V., Ferrarini, M., Morabito, F., & Fronza, G. (2021). Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? Cells. https://doi.org/10.3390/cells10010098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.